Sleepy Don: Let's Take An Honest, Deeper Look at Trump’s Cognitive and Physical Decline
Is Donald Trump receiving treatment for early-stage Alzheimer’s disease?
The speculation centers on two datapoints: the now-famous bruise on the back of his right hand, and news that #Trump recently received an MRI.
A viral video by a medical professional suggested that the bruise pattern and the MRI schedule mirror the monthly infusion regimen for #Kisunla (#donanemab), an #Alzheimer’s drug that requires patients to undergo regular brain imaging to monitor for ARIA, a potentially dangerous swelling or bleeding.
https://michaeldsellers.substack.com/p/sleepy-don-lets-take-an-honest-deeper
#donanemab #alzheimer Donanemab: Speranza concreta contro l'Alzheimer da Lilly
🧠 Gehirn fit halten: Steht die Alzheimerforschung an einem Wendepunkt? 🤔
Neue #Medikamente wecken Hoffnung, aber es bleiben viele Fragezeichen. Der individuelle Lebensstil hat einen großen Einfluss auf die Entstehung und Genese der Krankheit. Darüber sprechen Professor Dr. Frank Jessen und Professor Dr. Alfredo Ramírez im aktuellen Unimagazin ▶️ https://uni.koeln/NYVVR
#uniköln #unicologne #uniklinikkoeln #Alzheimerforschung #Alzheimer #Gehirn #Lebensstil #Lecanemab #Donanemab
FDA Approves Label Change for Alzheimer’s Drug
Brain edema risk expected to be less with new donanemab dosing schedule
The real question is whether it works?
https://cnmri.com/2025/07/14/fda-approves-label-change-for-alzheimers-drug/
Will this be the death knell for Alzheimer’s monoclonal antibody treatments 🤔
Preprint on #Alzheimers drug deaths ignites dispute among authors
“Infighting among a group of prominent Alzheimer’s disease researchers has led to the withdrawal of a preprint they co-authored, which suggested a new Alzheimer’s drug markedly increases the risk of death. One scientist involved in the work charges the senior author failed to seek the go-ahead from his co-authors before posting an edited version of the article to a preprint server.”
#Lecanemab #Donanemab #Kisunla #amyloid #dementia
https://www.science.org/content/article/preprint-alzheimer-s-drug-deaths-ignites-dispute-among-authors
NICE rejects #Alzheimer’s drug #donanemab owing to cost and “significant health risks” | The BMJ
#Medicine #Dementia #Medications #Geriatrics #Neurology #Drugs
https://www.bmj.com/content/387/bmj.q2342?utm_source=etoc&utm_medium=email&utm_campaign=tbmj&utm_content=weekly&utm_term=20241101&uaa_id=bcc8c22efde10b08ab8a0ae8cb17af0c5c3cfc1dae30ae4bcab329dfe2dc911a&utm_campaign=This%20week%20in%20The%20BMJ&utm_medium=email&utm_source=adestra
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the “relatively small benefit” it provides does not outweigh its cost.1 The draft guidelines, issued on 23 October, say that while clinical trial data suggest that the monthly injection could slow disease progression by four to seven months in mild Alzheimer’s disease, there is a large cost to providing the drug, which is administered by monthly infusions and needs to be intensively monitored for side effects. The guidance advises, “Evidence from clinical trials suggests that cognitive function continues to worsen over time with donanemab added to current treatment, but at a slower rate than with placebo. But there is not enough evidence on the long-term effects of donanemab.” NICE has also …
Die Gesellschafterin
DrBob, 🧠 Mechanic
Notizie Italiane
Universität zu Köln
The Japan Times
Gute Pillen – Schlechte Pillen
Matteo Cesari 